SCHEMBL20575845

SCHEMBL20575845

CC(C)(C)OC(=O)NC12CCC(N)(CC1)CC2

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.41
MAPK1 P28482 1/20 0.41
KMT2A Q03164 1/20 0.41
CTSL P07711 1/20 0.37
DGAT1 O75907 1/20 0.35
HSD11B1 P28845 1/20 0.34
HSD11B2 P80365 1/20 0.34
APLNR P35414 1/20 0.33
HDAC4 P56524 1/20 0.33
HDAC1 Q13547 1/20 0.33
DPP8 Q6V1X1 1/20 0.33
DPP9 Q86TI2 1/20 0.33
NFKB1 P19838 1/20 0.33
NFKB2 Q00653 1/20 0.33
RELA Q04206 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
GAA P10253 1/20 0.32
EPHX2 P34913 1/20 0.32
BTK Q06187 1/20 0.32
MAOA P21397 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL30216284 0.98 MEN1 (0.40) MEN1MAPK1KMT2ACTSLDGAT1
SCHEMBL22346156 0.89 MEN1 (0.39) MEN1MAPK1KMT2ACTSLDGAT1
SCHEMBL20974036 0.89 MEN1 (0.39) MEN1MAPK1KMT2ACTSLDGAT1
SCHEMBL23879650 0.86 HSD11B1 (0.47) MEN1MAPK1KMT2ACTSLDGAT1
SCHEMBL19188365 0.84 MEN1 (0.38) MEN1MAPK1KMT2ACTSLDGAT1
SCHEMBL11953286 0.84 MEN1 (0.35) MEN1MAPK1KMT2ACTSLDGAT1
SCHEMBL30562194 0.84 MEN1 (0.40) MEN1MAPK1KMT2ACTSLDGAT1
SCHEMBL1536186 0.84 MEN1 (0.40) MEN1MAPK1KMT2ACTSLDGAT1
SCHEMBL24031854 0.83 MEN1 (0.41) MEN1MAPK1KMT2ACTSLDGAT1
SCHEMBL20243118 0.83 MEN1 (0.41) MEN1MAPK1KMT2ADGAT1APLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3704090-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-05-27 EP disclosed
EP-3710428-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-25 EP disclosed
EP-3704094-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-11 EP disclosed
US-12404248-B2 IRE1 small molecule inhibitors CORNELL UNIVERSITY (US) 2025-09-02 US disclosed
US-20250195513-A1 DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE BEIGENE, LTD. (KY) 2025-06-19 US disclosed
US-20250145594-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2025-05-08 US disclosed
US-20250122188-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2025-04-17 US disclosed
US-20250019376-A1 CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS MERCK SHARP & DOHME LLC (US) 2025-01-16 US disclosed
US-12138265-B2 Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2024-11-12 US disclosed
EP-4201924-B1 IRE1 SMALL MOLECULE INHIBITORS UNIV CORNELL (US) 2024-10-23 EP disclosed
US-11021466-B2 IRE1 small molecule inhibitors CORNELL UNIVERSITY (US) 2021-06-01 US disclosed
US-20200383984-A1 HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2020-12-10 US disclosed
US-20200383984-A1 HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2020-12-10 US disclosed
US-20200317681-A1 TRIAZOLO-AZEPINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2020-10-08 US disclosed
US-20200291032-A1 PYRIMIDINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2020-09-17 US disclosed
WO-2020117634-A1 IRE1 SMALL MOLECULE INHIBITORS CORNELL UNIVERSITY (US) 2020-06-11 WO disclosed
US-20200157079-A1 IRE1 Small Molecule Inhibitors QUENTIS THERAPEUTICS, INC. (US) 2020-05-21 US disclosed
US-20200157079-A1 IRE1 Small Molecule Inhibitors QUENTIS THERAPEUTICS, INC. (US) 2020-05-21 US disclosed
US-10336762-B2 Pyrrolo[1,2-b]pyridazine derivatives GILEAD SCIENCES, INC. (US) 2019-07-02 US disclosed
US-20180346446-A1 IRE1 SMALL MOLECULE INHIBITORS CORNELL UNIVERSITY 2018-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200383984-A1 HETEROARYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC USE CDK9, IRAK1, CSNK1A1 MEN1 4397/4885MAPK1 177/4885KMT2A 1264/4885
US-20200317681-A1 TRIAZOLO-AZEPINE DERIVATIVES HUWE1, APP, PSEN1 MEN1 998/4885MAPK1 980/4885KMT2A 2045/4885
US-20250122188-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 MEN1 4714/4885MAPK1 239/4885KMT2A 4320/4885
US-20250019376-A1 CHROMANE AMIDINE MONOBACTAM ANTIBIOTICS PAM, ACMSD, MGAM2 MEN1 270/4885MAPK1 352/4885KMT2A 1492/4885
US-20200157079-A1 IRE1 Small Molecule Inhibitors XBP1, ERN2, ERN1 MEN1 3601/4885MAPK1 914/4885KMT2A 2312/4885
US-20200291032-A1 PYRIMIDINE DERIVATIVES TYMS, DPYD, TYMP MEN1 2275/4885MAPK1 3096/4885KMT2A 2112/4885
US-11021466-B2 IRE1 small molecule inhibitors XBP1, ERN2, ERN1 MEN1 3601/4885MAPK1 914/4885KMT2A 2312/4885
US-12138265-B2 Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use CDK9, IRAK1, CSNK1A1 MEN1 4419/4885MAPK1 168/4885KMT2A 1222/4885
US-10336762-B2 Pyrrolo[1,2-b]pyridazine derivatives SDHB, CYP4F2, CYP1B1 MEN1 1506/4885MAPK1 1817/4885KMT2A 3113/4885
US-20250195513-A1 DEGRADATION OF IRAK4 BY CONJUGATION OF IRAK4 INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE IRAK4, IRAK2, IRAK3 MEN1 3739/4885MAPK1 1825/4885KMT2A 637/4885
US-20180346446-A1 IRE1 SMALL MOLECULE INHIBITORS XBP1, ERN2, ERN1 MEN1 3601/4885MAPK1 914/4885KMT2A 2312/4885
US-20250145594-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 MEN1 4684/4885MAPK1 339/4885KMT2A 4179/4885
US-12404248-B2 IRE1 small molecule inhibitors XBP1, ERN2, ERN1 MEN1 3601/4885MAPK1 914/4885KMT2A 2312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.